Not Yet RecruitingPhase 1

A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C

South Korea55 participantsStarted 2026-01-23

Plain-language summary

To evaluate the pharmacokinetic interactions of AD-231A, AD-231B, and AD-231C in healthy adult volunteers.

Who can participate

Age range19 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy adult volunteers aged ≥19 and \<65 years at the time of the screening visit * Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit Exclusion Criteria: * Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

What they're measuring

Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss)

Timeframe: pre-dose (0hour) to 24 hours post-dose on Day 14

Maximum concentration of drug in plasma at steady state (Cmax,ss)

Timeframe: pre-dose (0hour) to 24 hours post-dose on Day 14

Trial details

NCT IDNCT07312773

SponsorAddpharma Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-02-07

Contact for this trial

JaeHun Jung

+8247679615 jhjung@addpharma.co.kr

View on ClinicalTrials.gov More Hypertension trials